Block Listing Application

RNS Number : 4031T

Shield Therapeutics PLC

24 March 2021

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

Block Listing Application

London, UK, 24 March 2021:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® ( ferric maltol), has today made an application to the London Stock Exchange for a block listing of 2,500,000 ordinary shares of 1.5 pence each in the Company ("Block Listing Shares") to be admitted to trading on the London Stock Exchange ("Admission") and to be split between the schemes listed below.

The 2,500,000 Block Listing Shares are to be issued under the following schemes:

· Shield Therapeutics Retention Share Plan

· Shield Therapeutics plc 2016 Company Share Option Plan

· The Shield Therapeutics plc 2016 Long Term Incentive Plan

· Shield Therapeutics Retention and Performance Share Plan

Admission is expected to occur on 30 March 2021.

For further information, please contact:

Shield Therapeutics plc	[phone]
Tim Watts (CEO) Lucy Huntington-Bailey (Company Secretary and General Counsel)	[phone]
Nominated Adviser and Joint Broker
Peel Hunt LLP			[phone]
James Steel / Christopher Golden
Joint Broker
finnCap Ltd	[phone]
Geoff Nash / Matthew Radley/ Alice Lane
Walbrook PR - Financial PR & IR Adviser		[phone]
Paul McManus / Lianne Cawthorne	or [e-mail]

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

ALSFLFVDVEISFIL